Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | ALPG | P10696 | 1/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.32 |
| ▸ | ALPL | P05186 | 1/20 | 0.32 |
| ▸ | PTGES | O14684 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2496669 | 0.94 | CCR1 (0.35) | CCR1LMNA | |
| SCHEMBL2499572 | 0.92 | CCR1 (0.35) | CCR1 | |
| SCHEMBL18619611 | 0.92 | CCR1 (0.35) | CCR1KDM4ELMNAMAPTHSD17B10 | |
| SCHEMBL21586659 | 0.90 | CCR1 (0.34) | CCR1 | |
| SCHEMBL25586455 | 0.89 | CCR1 (0.39) | CCR1 | |
| SCHEMBL20230401 | 0.89 | CCR1 (0.37) | CCR1 | |
| SCHEMBL19275537 | 0.89 | CCR1 (0.34) | CCR1SMN1; SMN2 | |
| SCHEMBL2495760 | 0.88 | CCR1 (0.36) | CCR1 | |
| SCHEMBL20560059 | 0.86 | CCR1 (0.31) | CCR1 | |
| Lotilaner SCHEMBL16860871 | 0.86 | CCR1 (0.33) | CCR1LMNAPTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110245239-A1 | ORGANIC COMPOUNDS | ELANCO TIERGESUNDHEIT AG (CH) | 2011-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245239-A1 | ORGANIC COMPOUNDS | ACHE, VDAC1, VDAC2 | CCR1 4087/4885KDM4E 2444/4885LMNA 3796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.